India Plasma Fractionation Market 2024–2033

Reports Description

India Plasma Fractionation Market was valued at USD 352.6 Million in 2024 and is expected to reach USD 498.2 Million by 2033, at a CAGR of 4.1% during the forecast period 2024 – 2033.

Plasma fractionation is a process that separates and purifies various proteins from blood plasma to produce therapeutic products. This technique involves fractionating plasma into its component proteins, such as albumin, immunoglobulins, clotting factors, and others.

India Plasma Fractionation Market: Growth Factors

Advancements in technology

Advancements in technology are propelling the growth of the plasma fractionation market in India by enhancing the efficiency, safety, and scalability of plasma processing. Innovations in separation techniques, such as chromatography and filtration, enable more precise fractionation of plasma proteins, resulting in higher purity and yield of therapeutic products.

Automated systems streamline production processes, reducing labour costs and human errors while increasing throughput. Moreover, advances in monitoring and control systems ensure strict adherence to quality standards and regulatory requirements, bolstering confidence in the safety and efficacy of plasma-derived products.

Additionally, the adoption of single-use technologies minimizes the risk of cross-contamination and facilitates rapid changeovers between production runs, enabling manufacturers to respond swiftly to fluctuations in demand.

These technological advancements not only improve the overall efficiency and productivity of plasma fractionation facilities but also drive down manufacturing costs, making life-saving therapies more accessible to patients across India.

Rise in use of immunoglobulins

The rise in the use of immunoglobulins has significantly propelled the Indian plasma fractionation market. Immunoglobulins, also known as antibodies, play a crucial role in the body’s immune response, aiding in the recognition and neutralization of foreign pathogens.

With the increasing prevalence of immune-related disorders and infectious diseases, there has been a growing demand for immunoglobulin therapies to treat conditions such as primary immunodeficiency disorders, autoimmune diseases, and neurological disorders like Guillain-Barré syndrome.

Plasma fractionation, the process of separating plasma into its parts, including immunoglobulins, albumin, and clotting factors, enables the large-scale production of immunoglobulin products for therapeutic use.

As healthcare awareness grows and access to advanced medical treatments expands across India, the demand for immunoglobulin therapies has surged, driving the need for plasma fractionation facilities and technologies.

This trend has stimulated investments in plasma fractionation infrastructure, research and development of novel immunoglobulin products, and collaborations between pharmaceutical companies and plasma collection centers to ensure an adequate and sustainable supply of plasma-derived therapies to meet the rising healthcare needs of the Indian population.

Consequently, the Indian plasma fractionation market is experiencing significant growth, propelled by the increasing utilization of immunoglobulin therapies to address a diverse range of medical conditions.

India Plasma Fractionation Market: Restraints

Storage and transportation issues

Plasma, the liquid portion of blood containing proteins vital for various medical therapies, requires stringent storage conditions to maintain its efficacy. However, inadequate infrastructure and inconsistent power supply in many regions hinder the establishment of reliable storage facilities, leading to concerns regarding the integrity and safety of plasma products during transportation and storage.

Moreover, India’s vast geographical expanse exacerbates logistical challenges, with remote areas often facing limited access to temperature-controlled storage facilities and reliable transportation networks. These issues not only increase the risk of product degradation but also raise concerns about maintaining the cold chain, crucial for preserving the quality and potency of plasma-derived products.

Additionally, inadequate transportation infrastructure and inefficient distribution networks can result in delays, further impacting the availability of essential plasma-derived therapies for patients across the country.

As a result, addressing these storage and transportation challenges is imperative for the sustainable growth of the plasma fractionation market in India, necessitating investments in robust infrastructure, cold chain logistics, and regulatory measures to ensure the safe and efficient supply of plasma-derived products to healthcare facilities nationwide.

India Plasma Fractionation Market: Opportunities

Increasing healthcare expenditure

The surge in plasma collection centers in India has catalysed significant growth in the country’s plasma fractionation market. Plasma collection centers play a pivotal role in sourcing the raw material for plasma fractionation, which involves separating plasma into its various components such as albumin, immunoglobulins, and clotting factors.

With an increasing number of collection centers across India, there has been a substantial rise in the availability of plasma for fractionation purposes. This surge addresses critical needs, particularly in healthcare sectors reliant on plasma-derived products for treating a wide array of medical conditions, including immune deficiencies, bleeding disorders, and neurological diseases.

Moreover, the expansion of plasma collection infrastructure enhances accessibility, enabling a larger population to participate in plasma donation, thereby augmenting the overall pool of plasma resources.

As a result, the increased availability of plasma for fractionation not only meets the growing demand for plasma-derived therapies but also fosters innovation and advancements in medical research and development.

This synergy between the expansion of plasma collection centers and the growth of the plasma fractionation market underscores the pivotal role of infrastructure development in driving healthcare advancements and improving patient outcomes in India.

India Plasma Fractionation Market: Segmentation Analysis

India Plasma Fractionation market is segmented by product, application and region.  Based on product, the market is classified into albumin, immunoglobulin, coagulation factors and others. Immunoglobulin dominated the market in 2023 with a market share of 45.3% and is expected to keep its dominance during the forecast period 2024-2033.

Immunoglobulins play a pivotal role in propelling the plasma fractionation market in India. As critical components of the immune system, immunoglobulins, also known as antibodies, are extracted from plasma through a process called plasma fractionation.

In India, the rising prevalence of immunodeficiency disorders, autoimmune diseases, and infectious diseases has significantly heightened the demand for immunoglobulin-based therapies. The growing recognition of the efficacy of immunoglobulin therapies in treating various medical conditions has led to expanded indications and usage across a wide spectrum of diseases.

Additionally, the implementation of favourable government policies and initiatives aimed at improving access to healthcare services, coupled with increasing investments by pharmaceutical companies in research and development activities related to plasma-derived products, are contributing to the robust growth of the plasma fractionation market in India.

As a result, immunoglobulins stand as a driving force behind the expansion and sustainability of the plasma fractionation market in the country, offering promising prospects for both healthcare providers and patients alike.

Based on application, the market is classified into immunology & neurology, haematology, critical care, pulmonology, and others. Immunology & Neurology dominated the market in 2023 with a market share of 49.9% and is expected to keep its dominance during the forecast period 2024-2033.

The demand for plasma-derived products such as immunoglobulins, albumin, and clotting factors is driven by the increasing prevalence of autoimmune diseases, primary immunodeficiency disorders, and other conditions requiring immune modulation.

Additionally, neurology contributes to the market through the treatment of neurological disorders such as Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy, and multifocal motor neuropathy, where immunoglobulin therapies derived from plasma are pivotal.

As India witnesses a rise in the incidence of these conditions, coupled with growing awareness and accessibility to advanced medical treatments, the demand for plasma fractionation products continues to escalate.

This synergy between immunological and neurological advancements not only fuels market growth but also underscores the critical role of plasma fractionation in addressing diverse medical needs across India’s healthcare landscape.

In India, the plasma fractionation market is significantly influenced by advancements in both immunology and neurology. Immunology plays a crucial role as plasma, the primary raw material for fractionation, contains various proteins essential for the body’s immune response.

The demand for plasma-derived products such as immunoglobulins, albumin, and clotting factors is driven by the increasing prevalence of autoimmune diseases, primary immunodeficiency disorders, and other conditions requiring immune modulation.

Additionally, neurology contributes to the market through the treatment of neurological disorders such as Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy, and multifocal motor neuropathy, where immunoglobulin therapies derived from plasma are pivotal.

As India witnesses a rise in the incidence of these conditions, coupled with growing awareness and accessibility to advanced medical treatments, the demand for plasma fractionation products continues to escalate.

Report Scope

Feature of the Report	Details
Market Size in 2024	USD 352.6 Million
Projected Market Size in 2033	USD 498.2 Million
Market Size in 2023	USD 351.3 Million
CAGR Growth Rate	4.1% CAGR
Base Year	2023
Forecast Period	2024-2033
Key Segment	By Product, Application and Region
Report Coverage	Revenue Estimation and Forecast, Company Profile, Competitive Landscape, Growth Factors and Recent Trends
Country Scope	India
Buying Options	Request tailored purchasing options to fulfil your requirements for research.

India Plasma Fractionation Market: Regional Insight

By region, Plasma Fractionation market is segmented into East India, West India, North India and South India. West India dominated the India Plasma Fractionation market in 2023 with a market share of 39.4% and is expected to keep its dominance during the forecast period 2024-2033.

The West India region plays a pivotal role in propelling the plasma fractionation market in India through several key factors. Primarily, the region hosts major metropolitan areas like Mumbai and Pune, serving as economic and healthcare hubs, which attract substantial investment in medical infrastructure and research facilities.

This concentration of resources fosters advancements in plasma fractionation technologies and facilitates the development of cutting-edge treatment options. Furthermore, West India’s robust pharmaceutical industry, with prominent players establishing manufacturing facilities and research centers, drives innovation and production efficiency in plasma-derived therapeutics.

Additionally, the presence of leading academic institutions and healthcare centers in West India fosters collaborations between academia, industry, and healthcare providers, promoting knowledge exchange and enhancing clinical practices related to plasma fractionation.

India Plasma Fractionation Market: Recent Developments

• In May 2019, Reliance Life Sciences imported plasma from Taiwan to control the albumin shortage in Maharashtra.

• In August 2017, PlasmaGen BioSciences Pvt. Ltd. announced to creation a manufacturing facility in Karnataka, India and also aims to reach a turnover of USD 100-120 million in the next five years.

List of the prominent players in the India Plasma Fractionation Market:

• PlasmaGen BioSciences Pvt. Ltd.
• Reliance Life Sciences
• Biocon Limited
• Intas Pharmaceuticals Ltd.
• Bharat Serums and Vaccines Limited
• VIRCHOW BIOTECH
• Fusion Healthcare
• Kedrion S.p.A
• Hemarus
• Others

These key players are adopting various growth strategies such as mergers & acquisitions, joint ventures, expansion, strategic alliances, new product launches, etc. to enhance their business operations and revenues.

The India Plasma Fractionation Market is segmented as follows:

By Product

• Albumin
• Immunoglobulin
• Coagulation Factors
• Others

By Application

• Immunology & Neurology
• Haematology
• Critical Care
• Pulmonology
• Others

By Method

• Centrifugation
• Depth Filtration
• Chromatography
• Others

By End Use

• Hospitals & Clinics
• Clinical Research
• Others